SR9011
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAαwith a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ. It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.
SR9011
SR9011 is a research drug that was developed by Professor Thomas Burris of Scripps as an agonist of Rev-ErbAαwith a half-maximum inhibitory concentration (IC50) = 790 nM for Rev-Erbα and IC50 = 560 nM for Rev-ErbAβ. It has been used in the study of the regulation of the circadian rhythm and its links to immune system function, inflammation and cancer.
has abstract
SR9011 is a research drug that ...... tion, inflammation and cancer.
@en
CAS number
1379686-29-9
ChEMBL
FDA UNII code
VYI79FLZ6W
PubChem
Wikipage page ID
40,327,976
page length (characters) of wiki page
Wikipage revision ID
1,022,232,940
Link from a Wikipage to another Wikipage
CAS number
ChEMBL
ChemSpiderID
28,487,552
IUPAC name
PubChem
57,394,021
SMILES
CCCCCNCN1CCCC1
@en
StdInChIKey
PPUYOYQTTWJTIU-UHFFFAOYSA-N
@en
UNII
VYI79FLZ6W
@en
wikiPageUsesTemplate
hypernym
comment
SR9011 is a research drug that ...... tion, inflammation and cancer.
@en
label
SR9011
@en